Background: Being a central link between inflammation and coagulation, tissue factor (TF) and its inhibitor (TFPI) might be associated with the severity of acute pancreatitis (AP) and the development of organ failure (OF). Methods: The study comprises 9 severe AP patients with OF and 24 reference patients (11 mild AP and 13 severe AP without OF). Plasma samples were collected on admission. TF-induced thrombin generation in plasma samples was studied using the thrombogram method. In vivo thrombin generation was estimated by prothrombin fragment F1+2. Free and total TFPI levels were measured. To evaluate coagulation status the activated partial thromboplastin time, prothrombin time, platelet count, D-dimer, fibrinogen, antithrombin (AT) 3 and protein C (PC) were determined. Results: There was no significant difference in F1+2 levels between the patient groups. Patients with severe AP tended to show low platelet counts, PC and AT3 levels, and high D-dimer levels. In 11 patients the standard TF stimulation did not trigger thrombin generation in the thrombogram. All deaths occurred in these patients. Free TFPI levels and free/total TFPI ratios were significantly higher in these patients and in non-survivors. Conclusion: Failure of TF-initiated thrombin generation in the thrombogram assay explained by high levels of circulating free TFPI may be associated with OF and mortality in AP.

1.
Steinberg W, Tenner S: Acute pancreatitis. N Engl J Med 1994;330:1198–1210.
2.
Tenner S, Sica G, Hughes M, Noordhoek E, Feng S, Zinner M, Banks PA: Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology 1997;113:899–903.
3.
Mentula P, Kylanpaa ML, Kemppainen E, Jansson SE, Sarna S, Puolakkainen P, Haapiainen R, Repo H: Early prediction of organ failure by combined markers in patients with acute pancreatitis. Br J Surg 2005;92:68–75.
4.
Repo H, Harlan JM: Mechanisms and consequences of phagocyte adhesion to endothelium. Ann Med 1999;31:156–165.
5.
Neoptolemos JP, Raraty M, Finch M, Sutton R: Acute pancreatitis: the substantial human and financial costs. Gut 1998;42:886–891.
6.
Cuthbertson CM, Christophi C: Disturbances of the microcirculation in acute pancreatitis. Br J Surg 2006;93:518–530.
7.
Levi M, van der Poll T, ten Cate H: Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006;32:33–39.
8.
Gando S, Nanzaki S, Sasaki S, Kemmotsu O: Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998;79:1111–1115.
9.
Gando S, Kameue T, Matsuda N, Hayakawa M, Morimoto Y, Ishitani T, Kemmotsu O: Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003;109:119–124.
10.
Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O: Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002;30:1729–1734.
11.
Sawa H, Ueda T, Takeyama Y, Yasuda T, Matsumura N, Nakajima T, Ajiki T, Fujino Y, Suzuki Y, Kuroda Y: Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J Gastroenterol 2006;41:575–581.
12.
Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988;72:2020–2025.
13.
Sidelmann JJ, Bladbjerg EM, Gram J, Munster AM, Jespersen J: Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis. Blood Coagul Fibrinolysis 2008;19:405–409.
14.
Abdel Gader AM, Al-Mishari AA, Awadalla SA, Buyuomi NM, Khashoggi T, Al-Hakeem M: Total and free tissue factor pathway inhibitor in pregnancy hypertension. Int J Gynaecol Obstet 2006;95:248–253.
15.
Brodin E, Borvik T, Sandset PM, Bonaa KH, Nordoy A, Hansen JB: Coagulation activation in young survivors of myocardial infarction (MI) – a population-based case-control study. Thromb Haemost 2004;92:178–184.
16.
Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, Hatada T, Ishikura K, Yamada N, Sudo A, Uchida A, Nobori T: Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis. Clin Appl Thromb Hemost 2008;14:279–285.
17.
van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622–1627.
18.
MacCallum PK, Thomson JM, Poller L: Effects of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery. Thromb Haemost 1990;64:511–515.
19.
Teitel JM, Bauer KA, Lau HK, Rosenberg RD: Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin–antithrombin complex. Blood 1982;59:1086–1097.
20.
Pelzer H, Schwarz A, Stuber W: Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153–159.
21.
Hemker HC, Beguin S: Phenotyping the clotting system. Thromb Haemost 2000;84:747–751.
22.
Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Beguin S, Hemker HC: The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002;88:576–582.
23.
Bradley EL 3rd: A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993;128:586–590.
24.
Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH): Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327–1330.
25.
Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ Jr, Schwartz AL: The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995;95:1773–1781.
26.
Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S: The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000;83:589–591.
27.
Hemker HC, Al Dieri R, De Smedt E, Beguin S: Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006;96:553–561.
28.
Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S: The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002;32:249–253.
29.
Lasson A, Ohlsson K: Disseminated intravascular coagulation and antiprotease activity in acute human pancreatitis. Scand J Gastroenterol Suppl 1986;126:35–39.
30.
Lasson A, Ohlsson K: Consumptive coagulopathy, fibrinolysis and protease-antiprotease interactions during acute human pancreatitis. Thromb Res 1986;41:167–183.
31.
Maeda K, Hirota M, Ichihara A, Ohmuraya M, Hashimoto D, Sugita H, Takamori H, Kanemitsu K, Baba H: Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas 2006;32:87–92.
32.
Salomone T, Tosi P, Palareti G, Tomassetti P, Migliori M, Guariento A, Saieva C, Raiti C, Romboli M, Gullo L: Coagulative disorders in human acute pancreatitis: role for the D-dimer. Pancreas 2003;26:111–116.
33.
Radenkovic DV, Bajec DD, Karamarkovic AR: Discussion on applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas 2006;33:106–107.
34.
Radenkovic D, Bajec D, Karamarkovic A, Stefanovic B, Milic N, Ignjatovic S, Gregoric P, Milicevic M: Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas 2004;29:152–156.
35.
Yasuda T, Ueda T, Kamei K, Shinzaki W, Sawa H, Shinzeki M, Ku Y, Takeyama Y: Plasma tissue factor pathway inhibitor levels in patients with acute pancreatitis. J Gastroenterol 2009;44:1071–1079.
36.
Sidelmann JJ, Bladbjerg EM, Gram J, Munster AM, Jespersen J: Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis. Blood Coagul Fibrinolysis 2008;19:405–409.
37.
Lwaleed BA, Bass PS: Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006;208:327–339.
38.
Lindahl AK, Sandset PM, Abildgaard U: The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992;3:439–449.
39.
Broze GJ Jr, Lange GW, Duffin KL, MacPhail L: Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994;5:551–559.
40.
Petersen LC, Bjorn SE, Nordfang O: Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992;67:537–541.
41.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
42.
Lindstrom O, Kylanpaa L, Mentula P, Puolakkainen P, Kemppainen E, Haapiainen R, Fernandez JA, Griffin JH, Repo H, Petaja J: Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Crit Care 2006;10:R16.
43.
Esmon CT: Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract Res Clin Haematol 1999;12:343–359.
44.
Esmon CT: Crosstalk between inflammation and thrombosis. Maturitas 2004;47:305–314.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.